Lyell Immunopharma, Inc. Other Nonoperating Income (Expense)
Lyell Immunopharma, Inc. (LYEL) reported Other Nonoperating Income (Expense) of $398.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:OtherNonoperatingIncomeExpense · last filed 2026-08-06
- Lyell Immunopharma, Inc. other nonoperating income (expense) for the quarter ending 2026-06-30 was $398.00K, a 66.27% decline year-over-year.
- Lyell Immunopharma, Inc. other nonoperating income (expense) for the quarter ending 2026-03-31 was $17.91M, a 1267.48% increase year-over-year.
- Lyell Immunopharma, Inc. other nonoperating income (expense) for the quarter ending 2025-12-31 was -$15.76M, a 467.08% decline year-over-year.
- Lyell Immunopharma, Inc. other nonoperating income (expense) for the quarter ending 2025-09-30 was -$4.86M.
- Lyell Immunopharma, Inc. other nonoperating income (expense) for fiscal 2025 was -$18.12M, a 486.11% decline from fiscal 2024.
- Lyell Immunopharma, Inc. other nonoperating income (expense) for fiscal 2024 was $4.69M, a 154.28% increase from fiscal 2023.
- Lyell Immunopharma, Inc. other nonoperating income (expense) for fiscal 2023 was $1.85M, a 2.17% decline from fiscal 2022.
- Lyell Immunopharma, Inc. other nonoperating income (expense) for fiscal 2022 was $1.89M.
| Period end | Other Nonoperating Income (Expense) 3 month | Other Nonoperating Income (Expense) 6 month | Other Nonoperating Income (Expense) 9 month | Other Nonoperating Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $398.00K 10-Q · filed 2026-08-06 | $18.31M 10-Q · filed 2026-08-06 | $2.56M derived: sum of 3 quarters · filed 2026-08-06 | -$2.30M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $17.91M 10-Q · filed 2026-05-06 | $2.16M derived: sum of 2 quarters · filed 2026-05-06 | -$2.70M derived: sum of 3 quarters · filed 2026-05-06 | -$1.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$15.76M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$20.61M derived: sum of 2 quarters · filed 2026-03-12 | -$19.43M derived: sum of 3 quarters · filed 2026-08-06 | -$18.12M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$4.86M 10-Q · filed 2025-11-12 | -$3.68M derived: sum of 2 quarters · filed 2026-08-06 | -$2.37M 10-Q · filed 2025-11-12 | $1.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.18M 10-Q · filed 2026-08-06 | $2.49M 10-Q · filed 2026-08-06 | $6.78M derived: sum of 3 quarters · filed 2026-08-06 | $6.74M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.31M 10-Q · filed 2026-05-06 | $5.60M derived: sum of 2 quarters · filed 2026-05-06 | $5.56M derived: sum of 3 quarters · filed 2026-05-06 | $4.91M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $4.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $4.25M derived: sum of 2 quarters · filed 2026-03-12 | $3.60M derived: sum of 3 quarters · filed 2026-03-12 | $4.69M 10-K · filed 2026-03-12 |
| 2024-09-30 | -$43.00K 10-Q · filed 2025-11-12 | -$688.00K derived: sum of 2 quarters · filed 2025-11-12 | $402.00K 10-Q · filed 2025-11-12 | -$104.00K derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | -$645.00K 10-Q · filed 2025-08-12 | $445.00K 10-Q · filed 2025-08-12 | -$61.00K derived: sum of 3 quarters · filed 2026-03-12 | $1.52M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $1.09M 10-Q · filed 2025-05-13 | $584.00K derived: sum of 2 quarters · filed 2026-03-12 | $2.16M derived: sum of 3 quarters · filed 2026-03-12 | $1.84M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | -$506.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $1.07M derived: sum of 2 quarters · filed 2026-03-12 | $746.00K derived: sum of 3 quarters · filed 2026-03-12 | $1.85M 10-K · filed 2026-03-12 |
| 2023-09-30 | $1.58M 10-Q · filed 2024-11-07 | $1.25M derived: sum of 2 quarters · filed 2024-11-07 | $2.35M 10-Q · filed 2024-11-07 | $5.29M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-06-30 | -$326.00K 10-Q · filed 2024-08-07 | $774.00K 10-Q · filed 2024-08-07 | $3.71M derived: sum of 3 quarters · filed 2025-03-11 | $2.64M derived: sum of 4 quarters · filed 2025-03-11 |
| 2023-03-31 | $1.10M 10-Q · filed 2024-05-06 | $4.03M derived: sum of 2 quarters · filed 2025-03-11 | $2.97M derived: sum of 3 quarters · filed 2025-03-11 | $2.95M derived: sum of 4 quarters · filed 2025-03-11 |
| 2022-12-31 | $2.93M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $1.87M derived: sum of 2 quarters · filed 2025-03-11 | $1.85M derived: sum of 3 quarters · filed 2025-03-11 | $1.89M 10-K · filed 2025-03-11 |
| 2022-09-30 | -$1.07M 10-Q · filed 2023-11-07 | -$1.08M derived: sum of 2 quarters · filed 2023-11-07 | -$1.05M 10-Q · filed 2023-11-07 | -$1.09M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | -$14.00K 10-Q · filed 2023-08-08 | $21.00K 10-Q · filed 2023-08-08 | -$23.00K derived: sum of 3 quarters · filed 2024-02-28 | -$7.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $35.00K 10-Q · filed 2023-05-04 | -$9.00K derived: sum of 2 quarters · filed 2024-02-28 | $7.00K derived: sum of 3 quarters · filed 2024-02-28 | -$99.00K derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | -$44.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$28.00K derived: sum of 2 quarters · filed 2024-02-28 | -$134.00K derived: sum of 3 quarters · filed 2024-02-28 | -$161.00K 10-K · filed 2024-02-28 |
| 2021-09-30 | $16.00K 10-Q · filed 2022-11-08 | -$90.00K derived: sum of 2 quarters · filed 2022-11-08 | -$117.00K 10-Q · filed 2022-11-08 | -$71.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | -$106.00K 10-Q · filed 2022-08-04 | -$133.00K 10-Q · filed 2022-08-04 | -$87.00K derived: sum of 3 quarters · filed 2023-02-28 | -$59.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | -$27.00K 10-Q · filed 2022-05-10 | $19.00K derived: sum of 2 quarters · filed 2023-02-28 | $47.00K derived: sum of 3 quarters · filed 2023-02-28 | $76.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $46.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $74.00K derived: sum of 2 quarters · filed 2023-02-28 | $103.00K derived: sum of 3 quarters · filed 2023-02-28 | $1.53M 10-K · filed 2023-02-28 |
| 2020-09-30 | $28.00K 10-Q · filed 2021-11-12 | $57.00K derived: sum of 2 quarters · filed 2021-11-12 | $1.48M 10-Q · filed 2021-11-12 | |
| 2020-06-30 | $29.00K 10-Q · filed 2021-08-12 | $1.45M 10-Q · filed 2021-08-12 | ||
| 2019-12-31 | -$35.41M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |